Kisunla is an amyloid-targeting drug for people with mild cognitive impairment (MCI), as well as for people with mild dementia in the early stages of symptomatic Alzheimer’s disease with documented amyloid pathology.
Kisunla has demonstrated highly significant results for people with early symptoms of Alzheimer’s disease who urgently need effective treatment options.
Active ingredient: donanemab
Prescription medicine
